Conditions are getting a bit more challenging for the drugmaker.
Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback